Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.49 |
| ▸ | SLC33A1 | O00400 | 3/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011200 | 0.77 | LTB4R2 (0.42) | SLC33A1LTB4R2PPARG | |
| SCHEMBL4010282 | 0.76 | PPARG (0.43) | AGTR1LTB4R2PPARGKCNH2 | |
| SCHEMBL4017111 | 0.74 | AGTR1 (0.40) | AGTR1SLC33A1PPARG | |
| SCHEMBL4016028 | 0.73 | AGTR1 (0.52) | AGTR1SLC33A1PPARG | |
| SCHEMBL1888375 | 0.73 | AGTR1 (0.62) | AGTR1PPARGKCNH2 | |
| SCHEMBL4016474 | 0.71 | PPARG (0.45) | AGTR1SLC33A1LTB4R2PPARGKCNH2 | |
| SCHEMBL4014474 | 0.70 | LTB4R2 (0.49) | AGTR1LTB4R2PPARGKCNH2 | |
| SCHEMBL13277715 | 0.69 | AGTR1 (0.63) | AGTR1PPARGKCNH2 | |
| SCHEMBL1895131 | 0.69 | AGTR1 (0.63) | AGTR1SLC33A1PPARGKCNH2 | |
| SCHEMBL4158457 | 0.68 | LTB4R2 (0.45) | AGTR1SLC33A1LTB4R2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074117-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |